Alliance Pharma Regulatory News (APH)

4 Oct 2007 14:35

Alliance Pharma PLC04 October 2007 For Immediate Release 4 October 2007 ALLIANCE PHARMA PLC ("Alliance" or "the Company") Director Share Purchase Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announcesthat Andrew Smith, a non-executive director, yesterday made a purchase of100,000 ordinary shares of 1p each in the Company at a price of 8.85p. This brings Mr Smith's total holding to 160,000 shares, representing 0.099% ofthe issued share capital of Alliance Pharma plc. For further information: Alliance Pharma plc + 44 (0) 1249 466966John Dawson, Chief Executive Richard Wright, Finance Directorwww.alliancepharma.co.uk Numis Securities + 44 (0) 20 7260 1000David PoutneyMichael Meade Buchanan Communications + 44 (0) 20 7466 5000Mark CourtRebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 34 branded pharmaceutical products. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to pharmaceutical wholesalers whichservice both hospital and retail pharmacies with their prescriptionrequirements. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange